Despite Data Concerns, Panel Recommends First-In-Class Toe Implant
This article was originally published in The Gray Sheet
Cartiva, a toe implant to treat osteoarthritis, received a strong recommendation from a panel of FDA experts despite suggestions that the device had not fully proven itself.
You may also be interested in...
Advisory Panel Recommends Approval For Link’s STAR Ankle Replacement
An FDA advisory panel recommended approval of Link Orthopedics' STAR ankle replacement system April 24 despite FDA reviewers' conclusion that results of the firm's pivotal trial are unclear
US FDA Complete Response Letter Rates Vary With Sponsor Size
Pink Sheet infographic illustrates benefits of big pharma’s resources and experience.
Is It Time To Promote US FDA’s Biosimilars Office Out Of OND?
Making the Office of Therapeutic Biologics and Biosimilars a stand-alone office in CDER may allow it to add more expertise, but is there an appetite for another reorganization?